Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Chimerix	Bicycle Therapeutics	VBI Vaccines	Intercept Pharmaceuticals	Syndax Pharmaceuticals
Symbol	NASDAQ:CMRX	NASDAQ:BCYC	NASDAQ:VBIV	NASDAQ:ICPT	NASDAQ:SNDX
Price Information
Current Price	$8.17	$30.36	$2.86	$17.75	$17.92
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.7	1.3	1.5	2.2	1.8
Analysis Score	4.5	3.5	3.6	4.1	3.4
Community Score	2.4	2.4	3.2	3.1	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.8	0.8	3.3	2.5
Earnings & Valuation Score	0.0	0.0	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$18.80	$43.00	$7.00	$42.83	$27.82
% Upside from Price Target	130.11% upside	41.63% upside	144.76% upside	141.27% upside	55.24% upside
Trade Information
Market Cap	$704.34 million	$729.49 million	$727.00 million	$588.63 million	$864.39 million
Beta	1.88	-0.21	2.14	1.85	1.8
Average Volume	1,003,429	163,456	5,925,049	1,145,946	850,631
Sales & Book Value
Annual Revenue	$12.52 million	$13.80 million	$2.22 million	$252 million	$1.52 million
Price / Sales	56.26	52.86	327.48	2.34	568.68
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.79 per share	$5.27 per share	$0.50 per share	$1.57 per share	$1.16 per share
Price / Book	4.56	5.76	5.72	11.31	15.45
Profitability
Net Income	$-112,580,000.00	$-30,610,000.00	$-54,810,000.00	$-344,680,000.00	$-56,050,000.00
EPS	($0.86)	($2.77)	($0.46)	($10.89)	($1.84)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-321.31%	-321.26%	-2,837.73%	-106.64%	-4,656.63%
Return on Equity (ROE)	-36.57%	-42.73%	-36.69%	-1,973.10%	-77.47%
Return on Assets (ROA)	-33.53%	-28.77%	-28.29%	-48.51%	-52.27%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.13%	0.10%	N/A	0.15%
Current Ratio	12.18%	9.63%	9.06%	3.44%	11.71%
Quick Ratio	12.18%	9.63%	8.95%	3.44%	11.71%
Ownership Information
Institutional Ownership Percentage	45.41%	42.68%	52.13%	85.77%	83.78%
Insider Ownership Percentage	9.00%	26.30%	10.50%	23.70%	9.50%
Miscellaneous
Employees	54	87	127	498	43
Shares Outstanding	86.21 million	24.03 million	254.20 million	33.16 million	48.24 million
Next Earnings Date	8/9/2021 (Estimated)	8/4/2021 (Estimated)	7/30/2021 (Estimated)	8/9/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Forecast: Bullish Sentiment Portends 74.72% Upside in 2021 stocksregister.com - May 12 at 5:27 PM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results americanbankingnews.com - May 12 at 2:38 PM
	Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial finance.yahoo.com - May 12 at 12:27 PM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up After Earnings Beat americanbankingnews.com - May 12 at 11:42 AM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $20.00 Price Target at Morgan Stanley americanbankingnews.com - May 12 at 11:08 AM
	Recap: Syndax Pharmaceuticals Q1 Earnings benzinga.com - May 11 at 10:57 PM
	Syndax Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation seekingalpha.com - May 11 at 7:36 PM
	Syndax: Q1 Earnings Snapshot chron.com - May 11 at 5:57 PM
	Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update finance.yahoo.com - May 11 at 5:57 PM
	DAX Stock News Today – Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent – Marketing Sentinel fintechzoom.com - May 8 at 3:00 PM
	Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent marketingsentinel.com - May 8 at 9:59 AM
	Syndax Pharmaceuticals Inc. (SNDX) has great growth outlook for 2021 marketingsentinel.com - May 5 at 10:58 AM
	Syndax Pharmaceuticals (SNDX) to Release Earnings on Tuesday americanbankingnews.com - May 5 at 10:56 AM
	Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 finance.yahoo.com - May 4 at 7:35 AM
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Buy" from Brokerages americanbankingnews.com - May 3 at 2:58 AM
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Here’s What’s Really Going On stocksregister.com - April 26 at 2:50 PM
	Dennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On Shares finance.yahoo.com - April 25 at 8:57 AM
	Syndax Pharmaceuticals Stock Appears To Be Significantly Overvalued uk.finance.yahoo.com - April 24 at 8:04 AM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 7.1% After Insider Buying Activity americanbankingnews.com - April 23 at 10:28 AM
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 Shares americanbankingnews.com - April 22 at 7:36 PM
	Pre-earnings Bullish Momentum Pattern and Trigger in Syndax Pharmaceuticals Inc cmlviz.com - April 22 at 3:19 PM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down Following Analyst Downgrade americanbankingnews.com - April 22 at 10:24 AM
	Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last? finance.yahoo.com - April 22 at 10:18 AM
	Wall Street Analyst Initiated Syndax Pharmaceuticals Inc. [SNDX]. What else is Wall St. saying dbtnews.com - April 21 at 11:34 PM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Sees Large Volume Increase americanbankingnews.com - April 21 at 12:58 PM

Date	Company	Brokerage	Action
5/12/2021	Chimerix	HC Wainwright	Boost Price Target
5/5/2021	Chimerix	Maxim Group	Initiated Coverage
4/12/2021	Chimerix	Jonestrading	Reiterated Rating
3/31/2021	Chimerix	Jefferies Financial Group	Initiated Coverage
3/31/2021	Chimerix	Wedbush	Initiated Coverage
5/9/2019	Chimerix	Cowen	Reiterated Rating
3/6/2019	Chimerix	Citigroup	Lower Price Target
5/11/2021	Bicycle Therapeutics	Oppenheimer	Boost Price Target
5/7/2021	Bicycle Therapeutics	Piper Sandler	Boost Price Target
4/26/2021	Bicycle Therapeutics	JMP Securities	Initiated Coverage
1/20/2021	Bicycle Therapeutics	Cantor Fitzgerald	Boost Price Target
9/10/2020	Bicycle Therapeutics	Canaccord Genuity	Boost Price Target
11/14/2019	Bicycle Therapeutics	Roth Capital	Initiated Coverage
9/11/2019	Bicycle Therapeutics	The Goldman Sachs Group	Upgrade
8/26/2020	VBI Vaccines	Raymond James	Upgrade
6/29/2020	VBI Vaccines	BMO Capital Markets	Reiterated Rating
5/6/2021	Intercept Pharmaceuticals	Stifel Nicolaus	Lower Price Target
3/8/2021	Intercept Pharmaceuticals	Needham & Company LLC	Lower Price Target
3/1/2021	Intercept Pharmaceuticals	B. Riley	Lower Price Target
3/1/2021	Intercept Pharmaceuticals	Chardan Capital	Lower Price Target
1/15/2021	Intercept Pharmaceuticals	Bank of America	Downgrade
5/13/2021	Syndax Pharmaceuticals	Robert W. Baird	Reiterated Rating
5/12/2021	Syndax Pharmaceuticals	Morgan Stanley	Lower Price Target
12/8/2020	Syndax Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/8/2020	Syndax Pharmaceuticals	Smith Barney Citigroup	Boost Price Target
12/7/2020	Syndax Pharmaceuticals	BTIG Research	Boost Price Target
12/7/2020	Syndax Pharmaceuticals	Barclays	Boost Price Target
5/25/2020	Syndax Pharmaceuticals	Nomura	Reiterated Rating

(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources